Tucatinib | List of Frontiers open access articles

Original Research

Published on 02 Oct 2023

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer

in Breast Cancer

Peter A. Kaufman
Edward Neuberger
Naomi R. M. Schwartz
Shu Wang
Yutong Liu
Ling-I Hsu
Karen Bartley
Matthew T. Blahna
Brian T. Pittner
Gabriel Wong

Frontiers in Oncology

doi 10.3389/fonc.2023.1264861

9,978 views
10 citations

Original Research

Published on 04 Aug 2020

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives

in Women's Cancer

Qiuji Wu
Weiting Liao
Mengxi Zhang
Jiaxing Huang
Pengfei Zhang
Qiu Li

Frontiers in Oncology

doi 10.3389/fonc.2020.01336

11,380 views
39 citations

Original Research

Published on 07 Jan 2026

Anti-HER2-targeted therapies: effects on human in vitro blood-brain barrier models

in CNS Drug Delivery

Carolin J. Curtaz
Rebecca Gebert
Achim Wöckel
Patrick Meybohm
Malgorzata Burek

Frontiers in Drug Delivery

doi 10.3389/fddev.2025.1700455

1,038 views

Review

Published on 30 Aug 2023

Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges

in Pharmacology of Anti-Cancer Drugs

Isha Bansal
Amit Kumar Pandey
Munindra Ruwali

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1244597

9,793 views
23 citations

Case Report

Published on 05 Jan 2026

Case Report: Pathological complete response yet early brain relapse in HER2-positive breast cancer: a case-based review

in Cancer Immunity and Immunotherapy

Jing Feng
Yujun Tong
Zhen Zhang
Yuanli He

Frontiers in Immunology

doi 10.3389/fimmu.2025.1668995

1,691 views

Original Research

Published on 10 Mar 2025

Signal detection and safety analysis of three tyrosine kinase inhibitors for HER-2 positive breast cancer: a retrospective study based on the FAERS database

in Pharmacoepidemiology

Xiting Tang
Chengliang Wang
Yanwei Li
Jing Tang
Guoping Zhang
Li Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1538881

3,464 views
3 citations

Original Research

Published on 24 Jan 2024

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)

in Pharmacology of Anti-Cancer Drugs

Yiwen Bao
Jiaju Chen
Luting Duan
Fujue Wang
Han Lai
Zeming Mo
Weiliang Zhu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1288362

5,475 views
12 citations

Review

Published on 16 Feb 2022

Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review

in Breast Cancer

Yajing Chi
Mao Shang
Liang Xu
Heyi Gong
Rongjie Tao
Lihua Song
Baoxuan Zhang
Sha Yin
Binbin Cong
Huihui Li

Frontiers in Oncology

doi 10.3389/fonc.2022.811919

7,180 views
11 citations

Original Research

Published on 02 Feb 2024

ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity

in Viral Immunology

Snježana Mikuličić
Merha Shamun
Annika Massenberg
Anna-Lena Franke
Kirsten Freitag
Tatjana Döring
Johannes Strunk
Stefan Tenzer
Thorsten Lang
Luise Florin

Frontiers in Immunology

doi 10.3389/fimmu.2024.1335302

5,016 views
6 citations

Articles

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives

Anti-HER2-targeted therapies: effects on human in vitro blood-brain barrier models

Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges

Case Report: Pathological complete response yet early brain relapse in HER2-positive breast cancer: a case-based review

Signal detection and safety analysis of three tyrosine kinase inhibitors for HER-2 positive breast cancer: a retrospective study based on the FAERS database

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)

Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review

ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity